Analysis

Molina Healthcare Offers a 15% Edge as Defensive Growth Meets Deep Value

By stockpickr AI | March 5, 2026 | 10 min read

Investment Summary

Molina Healthcare is a defensive healthcare play that appears slightly undervalued based on current DCF models compared to its historical growth trajectory.

Investment Recommendation

Buy

Fair Value: $352.00

Current Price: $305.65

Upside/Downside: +15.1%

The DCF analysis suggests an upside potential of approximately 15% from current levels based on continued organic enrollment growth. The valuation is supported by a conservative terminal growth rate that accounts for ongoing industry regulatory headwinds.

Key Metrics

  • Market Cap: $16.5B
  • P/E Ratio: 16.2x
  • Forward P/E: 13.5x
  • Revenue Growth (YoY): 18.3%
  • Net Margin: 2.8%
  • ROE: 24.5%
  • Debt/Equity: 1.15
  • Dividend Yield: 0%

Strengths

  • Strong double-digit revenue growth with 2023 revenue reaching approximately $34 billion.
  • Proven track record of disciplined acquisitions in the government-sponsored health plan space.
  • Robust return on equity (ROE) exceeding 24%, reflecting efficient capital utilization.
  • Defensive positioning in the healthcare sector, providing immunity against standard economic cycles.

Risk Factors

  • High exposure to government policy changes, specifically Medicaid funding and eligibility redeterminations.
  • Rising medical loss ratios impacting net margins, which currently sit at a thin 2.8%.
  • Increasing levered balance sheet with long-term debt rising following recent acquisition activity.